Hepatitis B Vaccine

Clinical Trials of New Vaccine Formulations and Dose Regimen
  • A. Goudeau
  • F. Dubois
  • J. Klein
  • A. Godefroy
  • J. Huchet
  • Y. Brossard
  • J. C. Soulié
  • C. Louq
  • F. Tron
Chapter
Part of the Applied Virology Research book series (AOTP, volume 1)

Abstract

The first results of active immunization against hepatitis B in humans were reported a little over 10 years ago (Maupas et al., 1976). Since then, several serum-derived hepatitis B (HB) vaccines have been proved safe, highly immunogenic and efficacious in various populations at risk (Stevens et al., 1984). However, the high cost of production has limited their use to high-risk volunteers in developed countries. Even there, it has been found difficult to expand immunization to all exposed individuals. In France, for instance, immunization of the estimated 1.5 million individuals at risk would cost around $100 million, i.e., 10-fold the cost of the entire rubella-prevention program. Endemic areas in which large-scale use of HB vaccines would be the most valuable are in Africa or Southeast Asia. Many countries in these areas simply cannot afford hepatitis B immunization unless prices of vaccines are significantly lowered. With currently available vaccines, immunization can be achieved by two means: (1) reducing the number of doses for primary immunization, and (2) lowering the concentration of HB s Ag in the vaccine.

Keywords

Newborn Infant Seroconversion Rate Primary Immunization Booster Injection Group Band 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barin, F., Goudeau, A., Denis, F., Yvonnet, B., Chiron, J. P., Coursaget, P., and Diop Mar, I. (1982). Lancet 1, 251–253.PubMedCrossRefGoogle Scholar
  2. Chiron, J. P., Coursaget, P., Yvonnet, B., Auger, F., Lee Quan, T., Barin, F., Denis, F., and Diop Mar, I. (1984). Lancet 1, 623–624.PubMedCrossRefGoogle Scholar
  3. Crosnier, J., Jungers, P., Courouce, A. M., Laplanche, A., Benhamou, E., Degos, F., LaCour, B., Prunet, P., Cerisier, Y., and Guesry, P. (1981). Lancet 1, 455–458; 797-800.PubMedCrossRefGoogle Scholar
  4. Goudeau, A., Dubois, F., Barin, F., Dubois, M. C., and Coursaget, P. (1983). Dev. Biol. Stand. 54, 267–284.PubMedGoogle Scholar
  5. Goudeau, A., Dubois, F., Jeussray, B., DuBois, M. C., Louq, C., Mazert, M. C., and Tron, F. (1984a). Proceedings of the IASL-EASL Symposium, Bern.Google Scholar
  6. Goudeau, A., Dubois, F., Dubois, M. C., Louq, C., and Mazert, M. C. (1984b). Lancet 2, 1091.PubMedCrossRefGoogle Scholar
  7. Maupas, P., Goudeau, A., Coursaget, P., Drucker, J., and Bagros, P. (1976). Lancet 1, 1367–1370.PubMedCrossRefGoogle Scholar
  8. Maupas, P., Chiron, J. P., Barin, F., Coursaget, P., Goudeau, A., Perrin, J., Denis, F., and Diop Mar, I. (1981). Lancet 1, 289–292.PubMedCrossRefGoogle Scholar
  9. Mazert, M. C., Chabanier, G., Adamowicz, P., and Gerfaux, G. (1983). Dev. Biol. Stand. 54, 53–62.PubMedGoogle Scholar
  10. Perrin, J., Ntareme, F., Coursaget, P., and Chiron, J. P. (1985). In Virus-Associated Cancers in Africa (A. O. Williams, G. T. O’Connor, and G. B. de The, C. A. Johnson, eds.), pp. 307–318, IARC., Lyons.Google Scholar
  11. Piazza, M., Picciotto, L., Willari, R., Guadagnino, V., Orlando, R., Isabella, L., Macchia, V., Memoli, A. M., Vegnente, A., Borelli, A. M., Scarcella, A., Cascioli, C., Cirrilo, C., Coppola, P., Isabella, E., and Parisi, G. (1985a). Lancet 1, 949–951.PubMedCrossRefGoogle Scholar
  12. Piazza, M., Piccioto, L., Villari, R., Guadagnino, V., Orlando, R., Macchia, V., Memoli, A. M., Vegnente, A., Guida, S., and Fusco, C. (1985b). Lancet 2, 1120–1121.PubMedCrossRefGoogle Scholar
  13. Stevens, C. E., Taylor, P. E., Tong, M. J., Toy, P. T., and Vyas, G. N. (1984). In Virale Hepatitis and Liver Disease (G. N. Vyas, J. L. Dienstag, and J. H. Hoffnagle, eds.), pp. 275–291, Grune & Stratton, Orlando, Florida.Google Scholar
  14. Szmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Olesko, W. R., William, D. C., Sadovsky, R., Morrison, J. M., and Kellner, A. (1980). N. Engl. J. Med. 303, 833–841.PubMedCrossRefGoogle Scholar
  15. Yvonnet, B., Coursaget, P., Petat, E., Tortey, E., Diouf, C., Barin, F., Denis, F., Diop Mar, I., and Chiron, J. P. (1984). J. Med. Virol. 14, 137–139.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • A. Goudeau
    • 1
  • F. Dubois
    • 1
  • J. Klein
    • 2
  • A. Godefroy
    • 2
  • J. Huchet
    • 3
  • Y. Brossard
    • 3
  • J. C. Soulié
    • 3
  • C. Louq
    • 4
  • F. Tron
    • 4
  1. 1.Institute of VirologyTours, CedexFrance
  2. 2.Center of Blood TransfusionChateaurouxFrance
  3. 3.Center of Perinatal Blood BiologyParis, Cedex 12France
  4. 4.Pasteur-VaccinsMarnes La CoquetteFrance

Personalised recommendations